Global Animal Vaccines Market, by Product Type (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, and Recombinant Vaccines), by Application (Companion Animal, Livestock Animal, Poultry, and Aquaculture), by Distribution Channel (Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 7,119.7 million in 2021, and is expected to exhibit a CAGR of 6.6% during the forecast period (2021-2028).

Recent advancements in technology and improved understanding of pathogenicity, immunology and epidemiology, and introduction of genetic engineering have opened new opportunities for preventing infectious diseases such as rabies, Lyme disease, cancer, and canine distemper. For instance, in December 2018, EvviVax, a biotechnology company, aims to offer novel therapeutic avenues to pet cancer patients, developed a novel vaccine called Tel-eVax that targets Telomerase, the enzyme that maintains telomeres and prevents them from shortening during cell division. Moreover, Tel-eVax has shown efficacy for canine B-cell Lymphoma in three trials and is currently being evaluated in other tumor types.

Global Animal Vaccines Market - Impact of Coronavirus (COVID – 19) Pandemic

Supply chain and manufacturing activities in India, Italy, Spain, U.K., and the U.S. have been disrupted due to the global lockdowns in the past few months, while countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of vaccines. Vaccination is a major requirement for animals to protect them from bacterial or viral infections, which might be delayed due to pandemic. For instance, Candioli Pharmaceuticals, an animal health business in Northern Italy, which was negatively impacted by the ongoing COVID-19, reported that the Italian market had slowed down and the workforce was reduced. Similarly, CZ Vaccines, which is headquartered in Spain, also experienced a slow-down as the country was under strict lockdown. Moreover, the workforce of CZ Vaccines switched to teleworking that impacted activities such as production and R&D.

Browse 28 Market Data Tables and 78 Figures spread through 180 Pages and in-depth TOC on Global Animal Vaccines Market, by Product Type (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, and Recombinant Vaccines), by Application (Companion Animal, Livestock Animal, Poultry, and Aquaculture), by Distribution Channel (Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global animal vaccines market, click the link below:

https://www.coherentmarketinsights.com/market-insight/animal-vaccines-market-4989

Viral outbreak in livestock population such as nipah virus, swine flu, canine influenza, bird flu, and avian influenza are expected to drive growth of the veterinary vaccine market over the forecast period. Nipah virus outbreak found in equine veterinarians in 2018 has influenced scientists to create vaccine, for global concerns. Furthermore, in 2018, the World Health Organization listed Nipah infection as a public health risk with epidemic potential.

Key Takeaways of the Global Animal Vaccines Market:

  • The global animal vaccines market is expected to exhibit a CAGR of 6.6% over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028), owing rising number of product launches and approvals. For instance, in November 2017, AgriLabs, a U.S. based biopharmaceutical company, received the U.S. Department of Agriculture (U.S.DA) approval of the first ever DNA vaccine licensed for chickens. The approval also represents the first for AgriLabs' ExactVac DNA technology with ENABL adjuvant, the first DNA vaccine approved for influenza for veterinary use, and among the first DNA vaccines approved in the U.S. for food animals.
  • Among product type, Attenuated Live Vaccines segment is expected to witness fastest growth in the global animal vaccines market over the forecast period. The growth of the segment is attributed to rapid research and development of attenuated live vaccines. For instance, according to the World Health Organization’s 2018 estimation, several modified-live (ML) rabies virus vaccine candidates such as SAD (Street Alabama Dufferin)-Bern vaccine, Vnukovo-32, and others have been developed for the oral immunization of animals in the past 35 years
  • Some of the major players operating in the global animal vaccines market include Merck & Co., Inc., Boehringer Ingelheim International GmbH., Zoetis Inc., Elanco Animal Health Incorporated, Ceva, HIPRA, Romvac Company Sa, Biovac, Vaxxinova International BV, and Biogénesis Bagó

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo